S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Stock market today: Asia follows Wall St up on hopes Fed will ease off rate hikes
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Is This The Collapse of Icahn Enterprises ?
20 Best Healthcare Dividend Stocks to Invest in
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
Laser breakthrough could send stock soaring 2,467% (Ad)
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
What Does the Airbnb Guidance Drop Say About Travel Demand?
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Stock market today: Asia follows Wall St up on hopes Fed will ease off rate hikes
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Is This The Collapse of Icahn Enterprises ?
20 Best Healthcare Dividend Stocks to Invest in
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
Laser breakthrough could send stock soaring 2,467% (Ad)
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
What Does the Airbnb Guidance Drop Say About Travel Demand?
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Stock market today: Asia follows Wall St up on hopes Fed will ease off rate hikes
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Is This The Collapse of Icahn Enterprises ?
20 Best Healthcare Dividend Stocks to Invest in
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
Laser breakthrough could send stock soaring 2,467% (Ad)
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
What Does the Airbnb Guidance Drop Say About Travel Demand?
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Stock market today: Asia follows Wall St up on hopes Fed will ease off rate hikes
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Is This The Collapse of Icahn Enterprises ?
20 Best Healthcare Dividend Stocks to Invest in
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
Laser breakthrough could send stock soaring 2,467% (Ad)
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
What Does the Airbnb Guidance Drop Say About Travel Demand?
NASDAQ:CPRX

Catalyst Pharmaceuticals (CPRX) Stock Forecast, Price & News

$11.64
+0.09 (+0.78%)
(As of 06/1/2023 ET)
Compare
Today's Range
$11.09
$11.65
50-Day Range
$11.50
$18.08
52-Week Range
$6.15
$22.11
Volume
1.68 million shs
Average Volume
2.17 million shs
Market Capitalization
$1.23 billion
P/E Ratio
13.23
Dividend Yield
N/A
Price Target
$21.50

Catalyst Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
84.7% Upside
$21.50 Price Target
Short Interest
Healthy
9.55% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.99
Upright™ Environmental Score
News Sentiment
0.25mentions of Catalyst Pharmaceuticals in the last 14 days
Based on 24 Articles This Week
Insider Trading
Selling Shares
$3.97 M Sold Last Quarter
Proj. Earnings Growth
16.52%
From $1.15 to $1.34 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.90 out of 5 stars

Medical Sector

65th out of 1,980 stocks

Pharmaceutical Preparations Industry

23rd out of 978 stocks


CPRX stock logo

About Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPRX Stock News Headlines

Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Catalyst Pharmaceuticals (NASDAQ:CPRX) Trading Down 17.3%
Catalyst Pharma (CPRX) Receives a Buy from H.C. Wainwright
See More Headlines

CPRX Price History

CPRX Company Calendar

Last Earnings
3/15/2023
Today
6/01/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CPRX
Employees
76
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$21.50
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$15.50
Forecasted Upside/Downside
+84.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$83.08 million
Pretax Margin
48.57%

Debt

Sales & Book Value

Annual Sales
$214.20 million
Cash Flow
$0.82 per share
Book Value
$3.15 per share

Miscellaneous

Free Float
91,120,000
Market Cap
$1.23 billion
Optionable
Optionable
Beta
1.11

Social Links


Key Executives

  • Patrick J. McEnanyPatrick J. McEnany
    Chairman, President & Chief Executive Officer
  • Steven R. MillerSteven R. Miller
    Chief Operating & Scientific Officer
  • Alicia GrandeAlicia Grande
    CFO, Treasurer, Principal Accounting Officer & VP
  • Gary IngenitoGary Ingenito
    Chief Medical & Regulatory Officer
  • Stanley Iyadurai
    Senior VP-Medical Affairs & Drug Discovery













CPRX Stock - Frequently Asked Questions

Should I buy or sell Catalyst Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CPRX shares.
View CPRX analyst ratings
or view top-rated stocks.

What is Catalyst Pharmaceuticals' stock price forecast for 2023?

4 Wall Street analysts have issued 1 year price objectives for Catalyst Pharmaceuticals' shares. Their CPRX share price forecasts range from $15.50 to $25.00. On average, they anticipate the company's share price to reach $21.50 in the next twelve months. This suggests a possible upside of 84.7% from the stock's current price.
View analysts price targets for CPRX
or view top-rated stocks among Wall Street analysts.

How have CPRX shares performed in 2023?

Catalyst Pharmaceuticals' stock was trading at $18.60 on January 1st, 2023. Since then, CPRX shares have decreased by 37.4% and is now trading at $11.64.
View the best growth stocks for 2023 here
.

Are investors shorting Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals saw a drop in short interest in May. As of May 15th, there was short interest totaling 9,490,000 shares, a drop of 15.2% from the April 30th total of 11,190,000 shares. Based on an average daily volume of 1,920,000 shares, the short-interest ratio is currently 4.9 days. Currently, 9.6% of the company's stock are short sold.
View Catalyst Pharmaceuticals' Short Interest
.

When is Catalyst Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our CPRX earnings forecast
.

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) released its quarterly earnings data on Wednesday, March, 15th. The biopharmaceutical company reported $0.22 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.21 by $0.01. The biopharmaceutical company earned $60.76 million during the quarter, compared to the consensus estimate of $60.64 million. Catalyst Pharmaceuticals had a net margin of 38.76% and a trailing twelve-month return on equity of 34.72%.

What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings?

Catalyst Pharmaceuticals updated its FY 2023 earnings guidance on Friday, May, 26th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $375.00 million-$385.00 million, compared to the consensus revenue estimate of $381.54 million.

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Who are Catalyst Pharmaceuticals' major shareholders?

Catalyst Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.54%), State Street Corp (7.11%), Dimensional Fund Advisors LP (2.25%), Geode Capital Management LLC (1.75%), Two Sigma Advisers LP (1.49%) and Jupiter Asset Management Ltd. (1.35%). Insiders that own company stock include Alicia Grande, Brian Elsbernd, Carmen Jeffrey Del, Charles B O'keeffe, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller.
View institutional ownership trends
.

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalyst Pharmaceuticals' stock price today?

One share of CPRX stock can currently be purchased for approximately $11.64.

How much money does Catalyst Pharmaceuticals make?

Catalyst Pharmaceuticals (NASDAQ:CPRX) has a market capitalization of $1.23 billion and generates $214.20 million in revenue each year. The biopharmaceutical company earns $83.08 million in net income (profit) each year or $0.88 on an earnings per share basis.

How can I contact Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The official website for the company is www.catalystpharma.com. The biopharmaceutical company can be reached via phone at (305) 420-3200, via email at bkorb@troutgroup.com, or via fax at 305-529-0933.

This page (NASDAQ:CPRX) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -